$Day One’s OJEMDA™ (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Common Form of Childhood Brain Tumor$

PremiumPress Releases

Day One’s OJEMDA™ (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Common Form of Childhood Brain Tumor

3d ago

DAWN

PremiumCompany Announcements

A New Cause for Concern: Day One Biopharmaceuticals, Inc. Adds a New Regulation Risk

2M ago

DAWN

PremiumCompany Announcements

Day One Biopharmaceuticals Updates Corporate Presentation

2M ago

DAWN

PremiumPress Releases

Day One Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Progress

2M ago

DAWN

PremiumPress Releases

Day One to Present at the 42nd Annual J.P. Morgan Healthcare Conference

4M ago

DAWN

PremiumPress Releases

Day One Announces Tovorafenib FIREFLY-1 Data Published in Nature Medicine

5M ago

DAWN

More DAWN News >

DAWN News on the Web

2024-04-25

Day One comments from call weighing on sentiment, says BofA

The Fly

Neutral

2024-04-24

Analysts Offer Insights on Healthcare Companies: Neurocrine (NBIX), Day One Biopharmaceuticals (DAWN) and Roche Holding AG (OtherRHHVF)

TipRanks News

Bullish

2024-04-23

Day One should rally to $17.50-$18 on approval, says JonesResearch

The Fly

Neutral

2024-04-23

Day One’s OJEMDA™ , the Most Common Form of Childhood Brain Tumor

Yahoo Finance

Neutral

2024-04-23

JPMorgan sees Day One moving to 'high-teens to low-$20s' after approval

The Fly

Neutral

2024-04-23

Buy Rating on Day One Biopharmaceuticals Amid FDA Approval and Strong Market Prospects

TipRanks News

Bullish

2024-04-22

Buy Rating Affirmed for Day One Biopharmaceuticals on Strong Tovorafenib Prospects and Market Impact

TipRanks News

Bullish

2024-03-28

Where Does Day One Biopharmaceuticals Inc (DAWN) Stock Fall in the Biotechnology Field After It Is Higher By 9.50% This Week?

Investors Observer

Neutral

News Score - Last 7 Days

Very Positive

DAWN

Sector Average

Media Buzz

This Week7 articles

Weekly Average1.75 articles

News Sentiment

This Week100%

Sector Average58%

See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is DAWN’s Media Buzz Sentiment?

7 articles about DAWN were published this week. In an average week, 1.75 articles are published.

What is DAWN’s weekly average amount of articles?

In an average week, 1.75 articles about DAWN are published.

What is DAWN’s News Sentiment?

100% of articles about DAWN were positive this week, compared to its sector average of 58%.

Healthcare Stocks that are Trending in the News

DAWNDay One Biopharmaceuticals

TAKTakeda Pharmaceutical Company

NBIXNeurocrine

AMEDAmedisys

MORFMorphic Holding

Showing the stocks with the most bullish news sentiment over the past week

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing